Aug 2026· Translational Neurodegeneration· Vol 15· 0 citations· 43 references
Medicine
TL;DR
Investigating the mechanisms underlying the reduction of p-tau217+ EVs to uncover AD therapeutic targets reveals a role of HSPA8 in regulating the MVB-mediated EV release and tau propagation, and highlights HSPA8 as a promising therapeutic target for modifying AD progression.
Abstract
Dysregulation of multivesicular bodies (MVBs) in Alzheimer’s disease (AD) contributes to aberrant tau secretion via extracellular vesicles (EVs). This may potentially explain our previous paradoxical observation of elevated free-form p-tau217 alongside reduced p-tau217+ EVs in plasma. This study aimed to investigate the mechanisms underlying the reduction of p-tau217+ EVs to uncover AD therapeutic targets. By integrating hippocampal spatial transcriptomics of human brain with EV proteomics of cerebrospinal fluid, we identified key regulators of p-tau217+ EV release. Subsequently, we investigated the mechanisms underlying the synthesis and secretion of p-tau217+ EVs. The regulatory roles of these candidate proteins were systematically evaluated through shRNA knockdown and interference with a synthetic peptide in both Aβ42-treated cells and AD model mice. Heat shock protein family A member 8 (HSPA8) was identified as a crucial regulator of EV biogenesis and release, mediating the Aβ–SNAP29 interaction to disrupt SNARE complex assembly and impair p-tau217+ EV secretion. In AD models, HSPA8 inhibition with shRNA rescued p-tau217+ EVs and improved cognitive function. Additionally, blocking the Aβ–SNAP29 interaction with a selective peptide inhibitor for HSPA8 reversed the decline in p-tau217+ EV and cognitive deficits. These findings reveal a role of HSPA8 in regulating the MVB-mediated EV release and tau propagation, and highlight HSPA8 as a promising therapeutic target for modifying AD progression.
Alzheimer’s Disease (AD) is characterised by two histopathological hallmarks, intracellular tau-containing neurofibrillary tangles and extracellular amyloid plaques containing β-amyloid (Aβ), a specific cleavage product of Amyloid Precursor Protein (APP). Initiation of Aβ-induced neuronal pathology, however, has been p...
A. Cording, Bhavna Verma, Adam Arous et al.· bioRxiv· 0 citations
Alzheimer's disease (AD) is characterized not only by amyloid-β and tau pathology but also by progressive failure of multicellular homeostasis. The P2X7 receptor (P2X7R), a low-affinity ATP-gated ion channel preferentially activated in extracellular ATP-rich pathological microenvironments, is well positioned to transla...
Intracellular neurofibrillary tangles formed from hyperphosphorylated tau and extracellular amyloid plaques containing aggregated Aβ-peptides, specific cleavage products of the Amyloid Precursor Protein (APP), are the primary histopathological hallmarks of Alzheimer’s Disease (AD), the leading cause of dementia in huma...
Bhavna Verma, A. Cording, Lewis Blincowe et al.· bioRxiv· 0 citations
A novel PINK1-(phospho)p47-STIP1 signaling axis that promotes dendritic complexity and protects against tau-induced neurodegeneration in cortical neurons is highlighted.
Sukanya Banerjee, Kent Z. Q. Wang, M. DeChellis-Marks et al.· Neurobiology of Disease· 0 citations
This review summarizes the progressive molecular events linking Αβ and tau pathology to neuroinflammation via the P2X7R-NLRP3 inflammasome axis, while underscoring the therapeutic potential of plant-derived bioactive compounds as well as synthetic molecules in mitigating the progression of Alzheimer’s disease.
Rishabh Goswami, Nidhi Sharma, V. Jhawat et al.· Asian Pacific Journal of Tro...· 0 citations
It is demonstrated that G3BP1 also stabilises the COPI vesicle protein beta-COP by promoting its interaction with the deubiquitinase USP10, which accelerates its proteasomal degradation.
Sarayu Ramakrishna, Laura Ryan, Sung-Min Son et al.· Cell Death and Differentiati...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.